UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,715	05/14/2007	Sergey I. Chernysh	SPSUP0100WOUS	4071
	7590 11/21/200 O BOISSELLE & SKI		EXAMINER	
1621 EUCLID AVENUE NINETEENTH FLOOR CLEVELAND, OH 44115			GUSSOW, ANNE	
			ART UNIT	PAPER NUMBER
			1643	
			MAIL DATE	DELIVERY MODE
			11/21/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/585,715	CHERNYSH ET AL.
Office Action Summary	Examiner	Art Unit
	ANNE M. GUSSOW	1643
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed on 11 Jan. This action is FINAL. Since this application is in condition for allowance of the condition of the condition. 	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) Claim(s) <u>1-26</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-26</u> are subject to restriction and/or	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and any objection to the Replacement drawing sheet(s) including the correct any objected to by the Example 2.	cepted or b) objected to by the liderawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/585,715 Page 2

Art Unit: 1643

DETAILED ACTION

Sequence Requirements

- 1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). This application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Claims 3 and 4 contain sequences that are encompassed by the sequences rules and require sequence identifiers (SEQ ID numbers). Applicant is required to amend the claims with the corresponding SEQ ID numbers. Applicants' cooperation is requested in reviewing the entire disclosure for additional sequence disclosures that require sequence identifiers to ensure that the application is in sequence compliance.
- Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
- 3. APPLICANT IS GIVEN THE TIME ALLOTED IN THIS OFFICE ACTION WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In

no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to the undersigned.

Election/Restrictions

4. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

To have a general inventive concept under PCT rule 13.1, the inventions need to be linked by a special technical feature. The special technical feature recited in claim 1 is a peptide comprising a compound having the general structural formula X_1 Trp Gly Gln X_2 . In view of this Fishleigh, et al. (US PAT 5,773,572 issued June 30, 1998) reads on the claim. Fishleigh, et al. teach polypeptides of SEQ ID Nos. 31, 30, and 46 each of which comprise the formula X_1 Trp Gly Gln X_2 . Therefore the technical feature recited in claim 1 is not special. Accordingly the groups are not so linked as to form a single general concept under rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide comprising of SEQ ID No. 1.

Group II, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 2.

Group III, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 3.

Group IV, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 4.

Group V, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 5.

Group VI, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 9.

Group VII, claim(s) 2, 3, in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 10.

Group VIII, claim(s) 2, 3 in part, 4 in part, 5 in part, 6-17 and 21-26 drawn to a polypeptide of SEQ ID No. 11.

Group IX, claim(s) 18-20, drawn to a nucleic acid, vector, and host cell.

5. The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: As set forth above, in view of the teachings of Fishleigh, et al., the groups are not so linked as to form a single general concept under PCT Rule 13.1 because the technical feature of claim 1 is not special.

Groups I-IX are related by the shared technical feature of the general structural formula X₁ Trp Gly Gln X₂, but Fishleigh, et al. teach a polypeptide comprising the general structural formula X₁ Trp Gly Gln X₂. Group I requires SEQ ID No. 1, which is not required for Groups II-IX; Group II requires SEQ ID No. 2, which is not required for Groups I, or III-IX; Group III requires SEQ ID No. 3, which is not required for Groups I-II or IV-IX; Group IV requires SEQ ID No. 4, which is not required for Groups I-III or V-IX; Group V requires SEQ ID No. 5, which is not required for Groups I-IV or VI-IX; Group VI

Application/Control Number: 10/585,715

Art Unit: 1643

requires SEQ ID No. 9, which is not required for Groups I-V or VII-IX; Group VII requires SEQ ID No. 10, which is not required for Groups I-VI or VIII-IX; Group VIII requires SEQ ID No. 11, which is not required for Groups I-VII or IX.

Page 5

6. Claim 1 link(s) inventions I-VIII. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claim 1. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 **Claims that require all the limitations of an allowable linking claim** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Application/Control Number: 10/585,715 Page 6

Art Unit: 1643

7. Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification:
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

 Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNE M. GUSSOW whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm. Application/Control Number: 10/585,715 Page 8

Art Unit: 1643

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gussow

November 14, 2008

/David J Blanchard/ Primary Examiner, Art Unit 1643